- U.K. health-cost regulator NICE has given a final recommendation for the use of Cell Therapeutics' (CTIC) Pixuvri for treating advanced B-cell non-Hodgkin lymphoma.
- Cell Therapeutics now hopes that NHS commissioners "will recognize the lack of suitable treatment options that exist for patients at this stage of the disease and list Pixuvri on hospital formularies as soon as possible."
- Cell Therapeutics expects to launch Pixuvri in England and Wales in the spring.
- Shares are +8.3%. (PR)